Drug manufacturer Gilead recently announced that a huge cut in pharmacy reimbursement for its HIV and hepatitis B medicines that uninsured individuals get for free
On April 6th, 2021, the New York legislature announced that it was delaying a controversial policy that would require the New York Medicaid program to
Representative Spanberger issued a press release yesterday announcing that she and 225 of her colleagues sent a letter to Acting HHS Secretary Norris Cochran, asking
On December 1, 2020, drug manufacturer Novo Nordisk Inc. announced that, effective January 1, 2021, it “will no longer facilitate ‘bill-to/ship-to’ distribution of 340B product
Thanks to efforts by RWC-340B members and other covered entity advocates, 217 members of the House of Representatives signed a bipartisan letter to Health and
By letter dated October 30, 2020, Novartis is notifying covered entities that are federal grantees that they will continue to receive 340B discounts at contract
On October 9, 2020, RWC-340B and two of its member 340B grantee clinics, Cempa Community Cares and Matthew 25 AIDS Services, Inc., filed a lawsuit
Today, RWC-340B submitted to a letter to Secretary of the U.S. Department of Health and Human Services (HHS) Alex Azar requesting that HHS initiate enforcement
In a notice sent to covered entities and other 340B program participants, Eli Lilly and Co. (Lilly) announced that, effective September 1, 2020, it is
On August 26, Second Sight Solutions, the owner of the 340B ESP™ platform, hosted the second in a series of webinars on 340B ESP™. The
